Drug Interaction:
NSAIDs include- Propionic acid- Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen Sodium, Oxaprozin Acetic acids- Diclofenac sodium, Etodolac, Indomethicin, Ketorolac, Nabumetone, Sulindac, Tolmetin Fenamates (anthralic acids) - Meclofenamate, Mefenamic acxid Oxicams- Piroxicam Refer- Ibuprofen
Indication:
Relief of moderate to pain
Treament of primary dysmenorrhea
Treatment of idiopathic heavy menstrual loss
Acute and chronic rheumatoid arthiritis and osteoarthiritis
NSAIDs include-
Propionic acid- Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen Sodium, Oxaprozin
Acetic acids- Diclofenac sodium, Etodolac, Indomethicin, Ketorolac, Nabumetone, Sulindac, Tolmetin
Fenamates (anthralic acids) - Meclofenamate, Mefenamic acxid
Oxicams- Piroxicam
Refer- Ibuprofen
Contra-Indications:
Warnings-
If diarrhea occurs with mefanamic acid or meclofenamate reduce dosage or temporarily discontinue use.
Dosages/ Overdosage Etc:
Relief of moderate to pain
Treament of primary dysmenorrhea
Treatment of idiopathic heavy menstrual loss
Acute and chronic rheumatoid arthiritis and osteoarthiritis
Mild to modrate pain-
50mg every 4 to 6 hours. Doses of 100mg may be required for optomal pain relief
Do not exceed daily dose of 400mg
Rheumatoid arthiritis-
Usual dose - 200 to 400mg per day in 3 or 4 equal doses.
Initial dose - initiate at a lower dose increase as needed to improve response
Do not exceed 400mg/day
Improvement may occur in a few days
Optimum benefits may not occur for 2 to 3 weeks
Childen - safety and efficacy in cvhildren < 14 years not established
Patient Information:
NSAIDs include-
Propionic acid- Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen Sodium, Oxaprozin
Acetic acids- Diclofenac sodium, Etodolac, Indomethicin, Ketorolac, Nabumetone, Sulindac, Tolmetin
Fenamates (anthralic acids) - Meclofenamate, Mefenamic acxid
Oxicams- Piroxicam
Refer- Ibuprofen
Pharmacology/ Pharmacokinetics:
Pharmacology-
Monotherapy with mefanamic acid and transexamic acid offer a simple therapy to be taken during menses
with reductions in mewnstrual blood loss of 25*35% and 50% respy. To increase the efficcay and and to
utilize complementary mechanisms of actions of mefenamic acid and tranexamic acid, a combination of these drugs
has been indicated in the treatment of menorrhagia, DUB, and bleeding due to IUCD and cervical conization.
A combination of mefanamic acid and transexamic acid which act by different mechanisms to target uterine bleeding
providing a better option for the management of abnormal uterine bleeding.